Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
- Positive: The company demonstrated resilience in its business model with positive cash flow and solid net product sales. The outlook for 2024 shows growth potential with a focus on key products like Rolvedon.
- Positive: Assertio's strategic measures to reduce operating costs, optimize non-personal promotion strategies, and pursue new business opportunities indicate a proactive approach to enhance financial performance.
- Negative: Declines in net product sales and gross margin, primarily due to generic competition for Indocin, impacted the company's financial results. Operating expenses increased, leading to a decrease in adjusted EBITDA compared to the previous year.
- Negative: The company incurred significant charges for loss on impairment of intangible assets, restructuring costs, and income tax expenses, affecting its profitability in the fourth quarter of 2023.
- Revenue decline from the prior year's fourth quarter due to generic competition and changes in sales mix.
- Increased operating expenses from the acquisition of Spectrum impacted the company's financial performance.
- Charges for loss on impairment of intangible assets and restructuring costs negatively affected the company's profitability.
- Adjusted EBITDA decreased significantly compared to the previous year's fourth quarter.
Insights
The reported net product sales decline from $49.9 million to $32.5 million in the fourth quarter for Assertio Holdings is a significant indicator of the company's performance, particularly when viewed against the backdrop of the pharmaceutical industry. This decrease is partially attributed to generic competition impacting key products such as Indocin. However, the introduction of Rolvedon, a new product, has partially offset these declines. The company's ability to generate a positive cash flow from operations despite a drop in sales is noteworthy, as it suggests operational efficiency and an effective cost management strategy.
Looking ahead, Assertio's guidance for 2024, with net product sales projected between $110 and $125 million and an adjusted EBITDA of $20 to $30 million, indicates a strategic focus on growth and profitability. Investors should consider the company's plans to optimize sales of Rolvedon and manage Indocin's pricing and volume. The gross margin decline from 88% to 70% is considerable and reflects changes in the sales mix and the impact of inventory step-up amortization, which investors should monitor as it affects profitability.
Assertio's cash and cash equivalents standing at $73.4 million, alongside a convertible debt of $40 million maturing in September 2027, provides a picture of the company's liquidity and debt position. The operational cash flow of $5.7 million for the quarter and $49.6 million year-to-date, inclusive of acquisition-related costs, is a positive sign of the company's cash-generating ability.
The pharmaceutical market is increasingly competitive with the introduction of generics, which can significantly erode the market share and profitability of branded drugs. Assertio's experience with Indocin reflects this trend. However, the company's commercial strategy in response to these challenges, particularly the focus on Rolvedon and the oncology segment, suggests an attempt to diversify its product portfolio and reduce reliance on any single product. The strategic steps taken to reduce operating costs and refine the organization are important for maintaining financial health in a challenging market environment.
Assertio's active pursuit of new business development opportunities to expand and diversify its asset base is a proactive approach in the face of generic competition. The success of these initiatives will be crucial for long-term sustainability and growth. Investors should watch for the company's ability to increase customer access and drive new volume growth for Rolvedon, which is positioned to potentially reach sales in excess of $100 million in the coming years.
The performance of Rolvedon in the targeted clinic segment and the resolution of channel inventory issues are positive developments from a medical product lifecycle perspective. The ongoing same-day dosing clinical study could provide further differentiation and potentially enhance the drug's marketability. The pharmaceutical industry places significant emphasis on clinical outcomes and product differentiation, which can influence prescribing habits and insurance coverage.
Assertio's focus on expanding its customer base in the G-CSF market through its in-person oncology team suggests an emphasis on specialized therapeutic areas where the company can leverage its expertise. The ability to effectively deploy resources in these areas can be critical for the adoption and success of new pharmaceutical products. Investors may benefit from understanding the clinical and market potential of Assertio's products, particularly as the company seeks to navigate the competitive landscape and maximize the economic opportunity of its portfolio.
Fourth Quarter Net Product Sales
2024 Full Year Outlook for Net Product Sales of
LAKE FOREST, Il., March 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended December 31, 2023.
| Financial Highlights (unaudited): | |||||||||||||
| Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||||
| (in millions, except per share amounts) | 2023 | 2022 | 2023 | 2022 | |||||||||
| Net Product Sales (GAAP) | $ | 32.5 | $ | 49.9 | $ | 149.5 | $ | 155.1 | |||||
| Net (Loss) Income (GAAP) | $ | (57.4 | ) | $ | 88.6 | $ | (331.9 | ) | $ | 109.6 | |||
| (Loss) Earnings Per Share (GAAP) | $ | (0.61 | ) | $ | 1.34 | $ | (4.67 | ) | $ | 2.03 | |||
| Adjusted EBITDA (Non-GAAP)1 | $ | 4.5 | $ | 33.4 | $ | 67.7 | $ | 101.6 | |||||
| Adjusted Earnings Per Share (Non-GAAP)1 | $ | 0.11 | $ | 0.32 | $ | 0.55 | $ | 1.19 | |||||
“Our fourth quarter results include positive indicators for the future, demonstrating the durability of Assertio’s business model. We delivered solid net product sales and positive cash flows from operations as we adapted our business strategy and aligned operating costs to the portfolio of products that will drive our growth and cash flows going forward,” said Heather Mason, interim Chief Executive Officer.
“Today we are providing guidance for 2024, targeting net product sales of
“Rolvedon continues to perform well in the targeted clinic segment, reflecting sequential quarter-over-quarter demand growth since launch. The channel inventory issues we previously discussed have been resolved, and we are fully committed to maximizing this asset. With our strategy now fully in place, we believe that Rolvedon can grow to sales in excess of
“Additionally, we have taken steps to substantially reduce our operating costs to match our product portfolio. We will continue to optimize Assertio’s non-personal promotion strategy while also deploying our excellent in-person oncology team to expand our customer base in the G-CSF market. We also continue to actively pursue new business development opportunities that can further expand and diversify our asset base,” concluded Mason.
Fourth quarter results included:
- Net product sales were
$32.5 million , decreased from$49.9 million in the prior year fourth quarter.- The declines in Indocin and Cambia following their respective generic entrants were partially offset by the addition of Rolvedon.
- Rolvedon net product sales were
$11.0 million in the fourth quarter, the first full quarter following the acquisition of Spectrum. During the quarter, the Company successfully addressed high levels of inventory in the channel and implemented an updated commercial strategy expected to drive sales growth throughout 2024 while maintaining pricing discipline. - Indocin net product sales in the fourth quarter were
$10.8 million , a$23.4 million decrease from the prior year quarter reflecting declining price and volumes due to a generic entrant late in 2023.
- Gross margin3 in the fourth quarter was
70% , decreased from88% in the prior year fourth quarter.- Inventory step-up amortization contributed nine percentage points of the decrease in margin, with the remaining reduction in margin primarily due to changes in sales mix from the addition of Rolvedon and decrease in higher margin Indocin and Cambia.
- SG&A expense was
$24.0 million , increased from$13.7 million in the prior year fourth quarter.- Results included approximately
$9.5 million in higher operating expense due to the acquisition of Spectrum. - In response to declining sales and gross profits, the Company refined its organization to further reduce its operating expense profile in the first quarter of 2024.
- Results included approximately
- Fourth quarter 2023 included the following other items:
- A charge of
$40.8 million for loss on impairment of intangible assets, primarily driven by a$36.0 million impairment of Indocin intangible asset. - A reduction in the fair value of contingent consideration resulted in a benefit of
$17.4 million driven by the revaluation of the Indocin contingent liability due to generic competition. - A charge of
$2.4 million for restructuring costs. - Income tax expense of
$25.5 million , primarily due to the impact of applying a valuation allowance against net deferred tax assets.
- A charge of
- Adjusted EBITDA was
$4.5 million , decreased from$33.4 million in the prior year fourth quarter, primarily due to Indocin generic competition and higher operating expenses from the acquisition of Spectrum.
2024 Full Year Financial Guidance
Assertio announced its initial 2024 operating guidance as follows:
| Net Product Sales (GAAP) | |
| Adjusted EBITDA (Non-GAAP)4 |
Balance Sheet and Cash Flow
- For the quarter ended December 31, 2023, cash and cash equivalents totaled
$73.4 million . - Convertible debt outstanding principal balance at December 31, 2023 was
$40.0 million and does not mature until September 2027. - Cash generated from operating activities quarter-to-date and year-to-date was
$5.7 million and$49.6 million , respectively, inclusive of transaction costs associated with the acquisition of Spectrum and supporting Spectrum’s working capital needs.
Board Update
Assertio announced the appointment of Sigurd (Sig) Kirk as an independent director, effective April 3, 2024. Kirk previously served for 11 years as Executive Vice President, Corporate Business Development at Allergan plc, which was acquired by AbbVie, Inc., where he led more than 75 deals. Prior to that, he served in multiple senior leadership roles at Barr Pharmaceuticals.
Conference Call and Investor Presentation Information
Assertio’s management will host a conference call to discuss its fourth quarter and full year 2023 financial results today:
| Date: | Monday, March 11, 2024 |
| Time: | 4:30 p.m. Eastern Time |
| Webcast (live and archive): | http://investor.assertiotx.com/overview/default.aspx (Events & Webcasts, Investor Page) |
| Dial-in numbers: | 1-646-968-2525, Conference ID 9752695 |
To access the live webcast, the recorded conference call replay, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. The replay will be available approximately two hours after the call on Assertio’s investor website.
About Assertio
Assertio is a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.
Investor Contact
Matt Kreps, Managing Director
Darrow Associates
M: 214-597-8200
mkreps@darrowir.com
Forward Looking Statements
The statements in this communication include forward-looking statements. Forward-looking statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs. Forward-looking statements speak only as of the date they are made or as of the dates indicated in the statements and should not be relied upon as predictions of future events, as there can be no assurance that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements can often, but not always, be identified by the use of forward-looking terminology including “believes,” “expects,” “may,” “will,” “should,” “seeks,” “intends,” “plans,” “pro forma,” “estimates,” “anticipates,” “designed,” or the negative of these words and phrases, other variations of these words and phrases or comparable terminology. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements, including: Assertio’s ability to grow sales of Rolvedon and the commercial success and market acceptance of Rolvedon and Assertio’s other products; Assertio’s ability to successfully develop and execute its sales, marketing and promotion strategies using its sales force and non-personal promotion model capabilities; the impact on sales and profits from the entry and sales of generics of Assertio’s products and/or other products competitive with any of Assertio’s products (including indomethacin suppositories compounded by hospitals and other institutions including a 503B compounder which we believe to be violation of certain provisions of the Food, Drug and Cosmetic Act); the timing and impact of additional generic approvals and uncertainty around the recent approvals and launches of generic Indocin products (which are not patent protected and now face generic competition as a result of the August 2023 approval and launch of generic indomethacin suppositories and January 2024 approval of a generic indomethacin oral suspension product); risks that any new businesses will not be integrated successfully or that the combined company will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer and/or cost more to realize than expected; expected industry trends, including pricing pressures and managed healthcare practices; Assertio’s ability to attract and retain executive leadership and key employees, including in connection with our ongoing search for a permanent CEO; the ability of Assertio’s third-party manufacturers to manufacture adequate quantities of commercially salable inventory and active pharmaceutical ingredients for each of Assertio’s products on commercially reasonable terms and in compliance with their contractual obligations to Assertio, and Assertio’s ability to maintain its supply chain which relies on single-source suppliers; the outcome of, and Assertio’s intentions with respect to, any litigation or government investigations, including pending and potential future shareholder litigation relating to the Spectrum Merger and/or the recent approval and launch of generic indomethacin suppositories, antitrust litigation, opioid-related government investigations, opioid-related litigation and related claims for negligence and breach of fiduciary duty against Assertio’s former insurance broker, as well as Spectrum’s legacy shareholder and other litigation and, and other disputes and litigation, and the costs and expenses associated therewith; Assertio’s financial cost and outcomes of clinical trials, including the extent to which data from the Rolvedon same-day dosing trial, if and when completed, may support ongoing commercialization efforts; Assertio’s compliance with legal and regulatory requirements related to the development or promotion of its products; variations in revenues obtained from commercialization agreements and the accounting treatment with respect thereto; Assertio’s common stock regaining and maintaining compliance with The Nasdaq Capital Market’s minimum closing bid requirement of at least
Non-GAAP Financial Measures
To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included information about non-GAAP measures of EBITDA, adjusted EBITDA, adjusted earnings, and adjusted earnings per share as useful operating metrics. The Company believes that the presentation of these non-GAAP financial measures, when viewed with results under GAAP and the accompanying reconciliation, provides supplementary information to analysts, investors, lenders, and the Company’s management in assessing the Company’s performance and results from period to period. The Company uses these non-GAAP measures internally to understand, manage and evaluate the Company’s performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP financial measures used by us may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
This release also includes estimated full-year non-GAAP adjusted EBITDA information, which the Company believes enables investors to better understand the anticipated performance of the business, but should be considered a supplement to, and not as a substitute for or superior to, financial measures calculated in accordance with GAAP. No reconciliation of estimated non-GAAP adjusted EBITDA to estimated net income is provided in this release because some of the information necessary for estimated net income such as income taxes, fair value change in contingent consideration, and stock-based compensation is not yet ascertainable or accessible and the Company is unable to quantify these amounts that would be required to be included in estimated net income without unreasonable efforts.
Specified Items
Non-GAAP measures presented within this release exclude specified items. The Company considers specified items to be significant income/expense items not indicative of current operations. Specified items may include adjustments to interest expense and interest income, income tax expense (benefit), depreciation expense, amortization expense, sales reserves adjustments for products the Company is no longer selling, stock-based compensation expense, fair value adjustments to contingent consideration or derivative liability, restructuring charges, amortization of fair value inventory step-up as a result of purchase accounting, transaction-related costs, gains or losses from adjustments to long-lived assets and assets not part of current operations, changes in valuation allowances on deferred tax assets, and gains or losses resulting from debt refinancing or extinguishment.
| ASSERTIO HOLDINGS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (in thousands, except per share amounts) (unaudited) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues: | |||||||||||||||
| Product sales, net | $ | 32,462 | $ | 49,866 | $ | 149,451 | $ | 155,121 | |||||||
| Royalties and milestones | 523 | 487 | 2,433 | 2,403 | |||||||||||
| Other revenue | — | — | 185 | (1,290 | ) | ||||||||||
| Total revenues | 32,985 | 50,353 | 152,069 | 156,234 | |||||||||||
| Costs and expenses: | |||||||||||||||
| Cost of sales | 9,721 | 6,015 | 27,020 | 18,748 | |||||||||||
| Research and development expenses | 1,024 | — | 2,843 | — | |||||||||||
| Selling, general and administrative expenses | 23,958 | 13,706 | 78,638 | 46,786 | |||||||||||
| Change in fair value of contingent consideration | (17,414 | ) | 11,841 | (25,538 | ) | 18,687 | |||||||||
| Amortization of intangible assets | 4,775 | 8,171 | 27,527 | 32,608 | |||||||||||
| Loss on impairment of intangible assets | 40,808 | — | 279,639 | — | |||||||||||
| Restructuring charges | 2,442 | — | 5,476 | — | |||||||||||
| Total costs and expenses | 65,314 | 39,733 | 395,605 | 116,829 | |||||||||||
| (Loss) income from operations | (32,329 | ) | 10,620 | (243,536 | ) | 39,405 | |||||||||
| Other income (expense): | |||||||||||||||
| Debt related expenses | — | — | (9,918 | ) | — | ||||||||||
| Interest expense | (755 | ) | (1,313 | ) | (3,380 | ) | (7,961 | ) | |||||||
| Other gain (loss) | 1,179 | (731 | ) | 2,780 | (278 | ) | |||||||||
| Total other income (expense) | 424 | (2,044 | ) | (10,518 | ) | (8,239 | ) | ||||||||
| Net (loss) income before income taxes | (31,905 | ) | 8,576 | (254,054 | ) | 31,166 | |||||||||
| Income tax (expense) benefit | (25,479 | ) | 79,975 | (77,888 | ) | 78,459 | |||||||||
| Net (loss) income and comprehensive (loss) income | $ | (57,384 | ) | $ | 88,551 | $ | (331,942 | ) | $ | 109,625 | |||||
| Basic net (loss) income per share | $ | (0.61 | ) | $ | 1.83 | $ | (4.67 | ) | $ | 2.33 | |||||
| Diluted net (loss) income per share | $ | (0.61 | ) | $ | 1.34 | $ | (4.67 | ) | $ | 2.03 | |||||
| Shares used in computing basic net (loss) income per share | 94,669 | 48,300 | 71,031 | 47,004 | |||||||||||
| Shares used in computing diluted net (loss) income per share | 94,669 | 67,074 | 71,031 | 54,669 | |||||||||||
| ASSERTIO HOLDINGS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share data) (unaudited) | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 73,441 | $ | 64,941 | |||
| Accounts receivable, net | 47,663 | 45,357 | |||||
| Inventories, net | 37,686 | 13,696 | |||||
| Prepaid and other current assets | 12,272 | 8,268 | |||||
| Total current assets | 171,062 | 132,262 | |||||
| Property and equipment, net | 770 | 744 | |||||
| Intangible assets, net | 111,332 | 197,996 | |||||
| Deferred tax asset | — | 80,202 | |||||
| Other long-term assets | 3,255 | 2,709 | |||||
| Total assets | $ | 286,419 | $ | 413,913 | |||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 13,439 | $ | 5,991 | |||
| Accrued rebates, returns and discounts | 58,137 | 49,426 | |||||
| Accrued liabilities | 18,213 | 12,181 | |||||
| Long-term debt, current portion | — | 470 | |||||
| Contingent consideration, current portion | 2,700 | 26,300 | |||||
| Other current liabilities | 954 | 948 | |||||
| Total current liabilities | 93,443 | 95,316 | |||||
| Long-term debt | 38,514 | 66,403 | |||||
| Contingent consideration | — | 22,200 | |||||
| Other long-term liabilities | 16,459 | 4,269 | |||||
| Total liabilities | 148,416 | 188,188 | |||||
| Commitments and contingencies | |||||||
| Shareholders’ equity: | |||||||
| Common stock, | 9 | 5 | |||||
| Additional paid-in capital | 789,537 | 545,321 | |||||
| Accumulated deficit | (651,543 | ) | (319,601 | ) | |||
| Total shareholders’ equity | 138,003 | 225,725 | |||||
| Total liabilities and shareholders' equity | $ | 286,419 | $ | 413,913 | |||
| ASSERTIO HOLDINGS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) | |||||||
| Year Ended December 31, | |||||||
| 2023 | 2022 | ||||||
| Operating Activities | |||||||
| Net (loss) income | $ | (331,942 | ) | $ | 109,625 | ||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 28,229 | 33,396 | |||||
| Amortization of debt issuance costs and Royalty Rights | 455 | 304 | |||||
| Loss on impairment of intangible assets | 279,639 | — | |||||
| Gain on extinguishment of debt | — | (1,046 | ) | ||||
| Recurring fair value measurements of assets and liabilities | (25,482 | ) | 18,939 | ||||
| Debt-related expenses | 9,918 | — | |||||
| Stock-based compensation | 9,158 | 7,504 | |||||
| Provisions for inventory and other assets | 3,288 | 3,265 | |||||
| Deferred income taxes | 76,201 | (80,375 | ) | ||||
| Changes in assets and liabilities, net of acquisition: | |||||||
| Accounts receivable | 48,669 | (996 | ) | ||||
| Inventories | (4,973 | ) | (6,593 | ) | |||
| Prepaid and other assets | (1,169 | ) | 8,019 | ||||
| Accounts payable and other accrued liabilities | (29,348 | ) | (10,113 | ) | |||
| Accrued rebates, returns and discounts | (12,313 | ) | (3,236 | ) | |||
| Interest payable | (726 | ) | (95 | ) | |||
| Net cash provided by operating activities | 49,604 | 78,598 | |||||
| Investing Activities | |||||||
| Purchases of property and equipment | (628 | ) | (274 | ) | |||
| Net cash acquired in Spectrum Merger | 1,950 | — | |||||
| Purchase of Sympazan | (419 | ) | (15,372 | ) | |||
| Purchase of Otrexup | — | (27,027 | ) | ||||
| Proceeds from the sale of investments | 2,194 | — | |||||
| Net cash provided by (used in) investing activities | 3,097 | (42,673 | ) | ||||
| Financing Activities | |||||||
| Proceeds from issuance of 2027 Convertible Notes | — | 70,000 | |||||
| Payments in connection with 2027 Convertible Notes | (10,500 | ) | — | ||||
| Payment of direct transaction costs related to convertible debt inducement | (1,119 | ) | — | ||||
| Payment in connection with 2024 Senior Notes | — | (70,750 | ) | ||||
| Payment of debt issuance costs | — | (4,084 | ) | ||||
| Payment of contingent consideration | (24,194 | ) | (7,845 | ) | |||
| Payment of Royalty Rights | (459 | ) | (1,297 | ) | |||
| Proceeds from issuance of common stock | — | 7,020 | |||||
| Payments related to the vesting and settlement of equity awards, net | (7,898 | ) | (838 | ) | |||
| Other financing activities | (31 | ) | — | ||||
| Net cash used in financing activities | (44,201 | ) | (7,794 | ) | |||
| Net increase in cash and cash equivalents | 8,500 | 28,131 | |||||
| Cash and cash equivalents at beginning of year | 64,941 | 36,810 | |||||
| Cash and cash equivalents at end of year | $ | 73,441 | $ | 64,941 | |||
| Supplemental Disclosure of Cash Flow Information | |||||||
| Net cash paid (refunded) for income taxes | $ | 4,031 | $ | (6,913 | ) | ||
| Cash paid for interest | $ | 3,651 | $ | 7,752 | |||
| RECONCILIATION OF GAAP NET (LOSS) INCOME TO NON-GAAP EBITDA and ADJUSTED EBITDA (in thousands) (unaudited) | ||||||||||||||||||
| Three Months Ended December 31, | Twelve months ended December 31, | |||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | Financial Statement Classification | ||||||||||||||
| GAAP Net (Loss) Income | $ | (57,384 | ) | $ | 88,551 | $ | (331,942 | ) | $ | 109,625 | ||||||||
| Interest expense | 755 | 1,313 | 3,380 | 7,961 | Interest expense | |||||||||||||
| Income tax (expense) benefit | 25,479 | (79,975 | ) | 77,888 | (78,459 | ) | Income tax (expense) benefit | |||||||||||
| Depreciation expense | 132 | 196 | 702 | 787 | Selling, general and administrative expenses | |||||||||||||
| Amortization of intangible assets | 4,775 | 8,171 | 27,527 | 32,608 | Amortization of intangible assets | |||||||||||||
| EBITDA (Non-GAAP) | (26,243 | ) | 18,256 | (222,445 | ) | 72,522 | ||||||||||||
| Adjustments: | ||||||||||||||||||
| Legacy product reserves(1) | — | — | (185 | ) | 1,290 | Other revenue | ||||||||||||
| Stock-based compensation | 2,642 | 2,388 | 9,158 | 7,504 | Selling, general and administrative expenses | |||||||||||||
| Change in fair value of contingent consideration(2) | (17,414 | ) | 11,841 | (25,538 | ) | 18,687 | Change in fair value of contingent consideration | |||||||||||
| Debt-related expenses(3) | — | — | 9,918 | — | Debt-related expenses | |||||||||||||
| Transaction-related expenses(4) | 361 | — | 8,900 | — | Selling, general and administrative expenses | |||||||||||||
| Loss on impairment of intangible assets(5) | 40,808 | — | 279,639 | — | Loss on impairment of intangible assets | |||||||||||||
| Restructuring costs(6) | 2,442 | — | 5,476 | — | Restructuring charges | |||||||||||||
| Other(7) | 1,855 | 892 | 2,820 | 1,592 | Multiple | |||||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 4,451 | $ | 33,377 | $ | 67,743 | $ | 101,595 | ||||||||||
(1) Represents removal of the impact of revenue adjustment to reserves for product sales allowances (gross-to-net-sales allowances) estimates related to previously divested products.
(2) The fair value of the contingent consideration is remeasured each reporting period, with changes in the fair value resulting from changes in the underlying inputs being recognized as a benefit or expense in operating expenses until the contingent consideration arrangement is settled.
(3) Debt-related expenses consist of an induced conversion expense of approximately
(4) Represents transaction-related expenses associated with the acquisition of Spectrum, which closed effective July 31, 2023.
(5) Represents the loss recognized in the period for the impairment of intangible assets.
(6) Restructuring charges represent non-recurring costs associated with the Company’s announced restructuring plan.
(7) Other for the three and twelve months ended December 31, 2023 and 2022 represents the following adjustments (in thousands):
| Three Months Ended December 31, | Twelve months ended December 31, | |||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | Financial Statement Classification | ||||||||||||||
| Amortization of inventory step-up | $ | 3,001 | $ | 107 | $ | 5,167 | $ | 807 | Cost of sales | |||||||||
| Interest income on short-term investments | (690 | ) | — | (2,403 | ) | — | Other gain (loss) | |||||||||||
| Derivative fair value adjustment | (456 | ) | 252 | 56 | 252 | Other gain (loss) | ||||||||||||
| Gain on debt extinguishment | — | (1,046 | ) | — | (1,046 | ) | Other gain (loss) | |||||||||||
| Loss recognized for expected credit loss reserve | — | 1,579 | — | 1,579 | Other gain (loss) | |||||||||||||
| Total Other | $ | 1,855 | $ | 892 | $ | 2,820 | $ | 1,592 | ||||||||||
| RECONCILIATION OF GAAP NET (LOSS) INCOME and NET (LOSS) INCOME PER SHARE TO NON-GAAP ADJUSTED EARNINGS and ADJUSTED EARNINGS PER SHARE(1) (in thousands, except per share amounts) (unaudited) | ||||||||||||||
| Three Months Ended December 31, 2023 | Three Months Ended December 31, 2022 | |||||||||||||
| Amount | Diluted EPS(2) | Amount | Diluted EPS(2) | |||||||||||
| Net (loss) income per share (GAAP) | $ | (57,384 | ) | $ | (0.61 | ) | $ | 88,551 | $ | 1.34 | ||||
| Add: Convertible debt interest expense and other income statement impacts, net of tax(2) | 566 | 1,169 | ||||||||||||
| Adjustments | ||||||||||||||
| Amortization of intangible assets | 4,775 | 8,171 | ||||||||||||
| Stock-based compensation | 2,642 | 2,388 | ||||||||||||
| Change in fair value of contingent consideration | (17,414 | ) | 11,841 | |||||||||||
| Contingent consideration cash payable(3) | (2,170 | ) | (6,854 | ) | ||||||||||
| Transaction-related expenses | 361 | — | ||||||||||||
| Loss on impairment of intangible assets | 40,808 | — | ||||||||||||
| Restructuring charges | 2,442 | — | ||||||||||||
| Other | 1,855 | 640 | ||||||||||||
| Increase (release) of deferred tax asset valuation allowance(4) | 33,165 | (80,375 | ) | |||||||||||
| Income taxes expense, as adjusted(5) | 1,877 | (4,047 | ) | |||||||||||
| Adjusted earnings (Non-GAAP) | $ | 11,523 | $ | 0.11 | $ | 21,484 | $ | 0.32 | ||||||
| Diluted shares used in calculation (GAAP)(2) | 94,669 | 67,074 | ||||||||||||
| Add: Dilutive effect of stock-based awards and equivalents(2) | 325 | — | ||||||||||||
| Add: Dilutive effect of 2027 Convertible Notes(2) | 9,768 | — | ||||||||||||
| Diluted shares used in calculation (Non-GAAP)(2) | 104,762 | 67,074 | ||||||||||||
(1) Certain adjustments included here are the same as those reflected in the Company’s reconciliation of GAAP net (loss) income to non-GAAP adjusted EBITDA and therefore should be read in conjunction with that reconciliation and respective footnotes.
(2) The Company uses the if-converted method with respect to its convertible debt to compute GAAP and Non-GAAP diluted earnings per share when the effect is dilutive. Under the if-converted method, the Company assumes the 2027 Convertible Notes, which were entered into on August 22, 2022, were converted at the beginning of each period presented and outstanding. As a result, interest expense, net of tax, and any other income statement impact associated with the 2027 Convertible Notes, net of tax, is added back to net income used in the diluted earnings per share calculation. As a result, interest expense, net of tax, associated with the 2027 Convertible Notes was added back to net loss used in the diluted earnings per share calculation for the three months ended December 31, 2023. For the three months ended December 31, 2022, interest expense, net of tax and the loss from the derivative fair value adjustment, net of tax, associated with the 2027 Convertible Notes, is added back to net income used in the diluted earnings per share calculation.
For the three months ended December 31, 2023, the Company’s potentially dilutive convertible debt under the if-converted method and potentially dilutive stock-based awards under the treasury-stock method were not included in the computation of GAAP diluted net (loss) income per share, because to do so would be anti-dilutive. However, the Company’s potentially dilutive convertible debt under the if-converted method and the potentially dilutive stock-based awards under the treasury-stock method were included in the computation of non-GAAP adjusted earnings and adjusted earnings per share because their effect was dilutive.
For the three months ended December 31, 2022, the Company’s potentially dilutive convertible debt under the if-converted method and potentially dilutive stock-based awards under the treasury stock method were included in both the computation of GAAP and non-GAAP diluted net income per share because their effect was dilutive.
(3) Represents the accrued cash payable of the INDOCIN contingent consideration for the respective period based on
(4) For the three-months ended December 31, 2023, represents the amount of income tax expense related to the recognition of a full valuation allowance against deferred tax assets. For the three-months ended December 31, 2022, represents the amount of income tax benefit related to the reversal of previously recorded valuation allowances.
(5) Represents the Company’s income tax benefit (expense) adjustment from the tax effect of pre-tax adjustments excluded from adjusted earnings. The tax effect of pre-tax adjustments excluded from adjusted earnings is computed at the blended federal and state statutory rate of
| RECONCILIATION OF GAAP NET (LOSS) INCOME and NET (LOSS) INCOME PER SHARE TO NON-GAAP ADJUSTED EARNINGS and ADJUSTED EARNINGS PER SHARE(1) (in thousands, except per share amounts) (unaudited) | ||||||||||||||
| Twelve Months Ended December 31, 2023 | Twelve Months Ended December 31, 2022 | |||||||||||||
| Amount | Diluted EPS(2) | Amount | Diluted EPS(2) | |||||||||||
| Net (loss) income (GAAP)(2) | $ | (331,942 | ) | $ | (4.67 | ) | $ | 109,625 | $ | 2.03 | ||||
| Add: Convertible debt interest expense and other income statement impacts, net of tax(2) | 2,535 | 1,560 | ||||||||||||
| Adjustments | ||||||||||||||
| Amortization of intangible assets | 27,527 | 32,608 | ||||||||||||
| Legacy products revenue reserves | (185 | ) | 1,290 | |||||||||||
| Stock-based compensation | 9,158 | 7,504 | ||||||||||||
| Debt-related expenses, net | 9,639 | — | ||||||||||||
| Change in fair value of contingent consideration | (25,538 | ) | 18,687 | |||||||||||
| Contingent consideration cash payable(3) | (13,443 | ) | (16,068 | ) | ||||||||||
| Transaction-related expenses | 8,900 | — | ||||||||||||
| Loss on impairment of intangible assets | 279,639 | — | ||||||||||||
| Restructuring charges | 5,476 | — | ||||||||||||
| Other | 2,820 | 1,340 | ||||||||||||
| Increase (release) of deferred tax asset valuation allowance(4) | 76,200 | (80,375 | ) | |||||||||||
| Income taxes expense, as adjusted(5) | (3,679 | ) | (11,340 | ) | ||||||||||
| Adjusted earnings (Non-GAAP) | $ | 47,107 | $ | 0.55 | $ | 64,831 | $ | 1.19 | ||||||
| Diluted shares used in calculation (GAAP)(2) | 71,031 | 54,669 | ||||||||||||
| Add: Dilutive effect of stock-based awards and equivalents(2) | 3,054 | — | ||||||||||||
| Add: Dilutive effect of 2027 Convertible Notes(2) | 10,932 | — | ||||||||||||
| Diluted shares used in calculation (Non-GAAP)(2) | 85,017 | 54,669 | ||||||||||||
(1) Certain adjustments included here are the same as those reflected in the Company’s reconciliation of GAAP net income to non-GAAP adjusted EBITDA and therefore should be read in conjunction with that reconciliation and respective footnotes.
(2) The Company uses the if-converted method with respect to its convertible debt to compute GAAP and Non-GAAP diluted earnings per share when the effect is dilutive. Under the if-converted method, the Company assumes the 2027 Convertible Notes, which were entered into on August 22, 2022, were converted at the beginning of each period presented and outstanding. As a result, interest expense, net of tax, associated with the 2027 Convertible Notes is added back to net loss used in the diluted earnings per share calculation for the twelve months ended December 31, 2023. For the twelve months ended December 31, 2022, interest expense, net of tax and the loss from the derivative fair value adjustment, net of tax, associated with the 2027 Convertible Notes, is added back to net income used in the diluted earnings per share calculation.
For the twelve months ended December 31, 2023, the Company’s potentially dilutive convertible debt under the if-converted method and potentially dilutive stock-based awards under the treasury-stock method were not included in the computation of GAAP diluted net (loss) income per share, because to do so would be anti-dilutive. However, the Company’s potentially dilutive convertible debt under the if-converted method and the potentially dilutive stock-based awards under the treasury-stock method were included in the computation of non-GAAP adjusted earnings and adjusted earnings per share because their effect was dilutive.
For the twelve months ended December 31, 2022, the Company’s potentially dilutive convertible debt under the if-converted method and potentially dilutive stock-based awards under the treasury-stock method were included in both the computation of GAAP and non-GAAP diluted net income per share because their effect was dilutive.
(3) Represents the accrued cash payable of the INDOCIN contingent consideration for the respective period based on
(4) For the twelve months ended December 31, 2023, represents the amount of income tax expense related to the recognition of a full valuation allowance against deferred tax assets. For the twelve months ended December 31, 2022, represents the amount of income tax benefit related to the reversal of previously recorded valuation allowances.
(5) Represents the Company’s income tax benefit (expense) adjustment from the tax effect of pre-tax adjustments excluded from adjusted earnings. The tax effect of pre-tax adjustments excluded from adjusted earnings is computed at the blended federal and state statutory rate of
1 Non-GAAP measures are reconciled to the corresponding GAAP measures in the schedules attached.
2 See “Non-GAAP Financial Measures” below for information about reconciling our Adjusted EBITDA guidance to Net Income.
3 Gross margin represents the ratio of net product sales less cost of sales to net product sales.
4 See “Non-GAAP Financial Measures” below for information about reconciling our Adjusted EBITDA guidance to Net Income.
FAQ
What were Assertio Holdings, Inc.'s fourth-quarter net product sales and cash flow from operations?
What is the 2024 full-year outlook for net product sales and adjusted EBITDA?
What were the key factors contributing to the decline in net product sales and gross margin in the fourth quarter of 2023?
Why did Assertio incur charges for loss on impairment of intangible assets, restructuring costs, and income tax expenses in the fourth quarter of 2023?
Who was appointed as an independent director at Assertio Holdings, Inc.?
